Neoplastic pancreatic epithelial cells are believed to die through caspase 8-dependent apoptotic cell death, and chemotherapy is thought to promote tumour apoptosis 1 . Conversely, cancer cells often disrupt apoptosis to survive 2,3 . Another type of programmed cell death is necroptosis (programmed necrosis), but its role in pancreatic ductal adenocarcinoma (PDA) is unclear. There are many potential inducers of necroptosis in PDA, including ligation of tumour necrosis factor receptor 1 (TNFR1), CD95, TNF-related apoptosis-inducing ligand (TRAIL) receptors, Toll-like receptors, reactive oxygen species, and chemotherapeutic drugs 4,5 . Here we report that the principal components of the necrosome, receptorinteracting protein (RIP)1 and RIP3, are highly expressed in PDA and are further upregulated by the chemotherapy drug gemcitabine. Blockade of the necrosome in vitro promoted cancer cell proliferation and induced an aggressive oncogenic phenotype. By contrast, in vivo deletion of RIP3 or inhibition of RIP1 protected against oncogenic progression in mice and was associated with the development of a highly immunogenic myeloid and T cell infiltrate. The immune-suppressive tumour microenvironment associated with intact RIP1/RIP3 signalling depended in part on necroptosisinduced expression of the chemokine attractant CXCL1, and CXCL1 blockade protected against PDA. Moreover, cytoplasmic SAP130 (a subunit of the histone deacetylase complex) was expressed in PDA in a RIP1/RIP3-dependent manner, and Mincle-its cognate receptor-was upregulated in tumour-infiltrating myeloid cells. Ligation of Mincle by SAP130 promoted oncogenesis, whereas deletion of Mincle protected against oncogenesis and phenocopied the immunogenic reprogramming of the tumour microenvironment that was induced by RIP3 deletion. Cellular depletion suggested that whereas inhibitory macrophages promote tumorigenesis in PDA, they lose their immune-suppressive effects when RIP3 or Mincle is deleted. Accordingly, T cells, which are not protective against PDA progression in mice with intact RIP3 or Mincle signalling, are reprogrammed into indispensable mediators of anti-tumour immunity in the absence of RIP3 or Mincle. Our work describes parallel networks of necroptosis-induced CXCL1 and Mincle signalling that promote macrophage-induced adaptive immune suppression and thereby enable PDA progression.
PDA, consistent with necrosome complex formation. To test whether necrosome formation was induced by chemotherapy, we treated PDAbearing mice with gemcitabine. Gemcitabine treatment increased expression of RIP1 and RIP3 in PDA in vivo (Fig. 1f, g) . Similarly, gemcitabine increased expression of Rip1 and Rip3 (also known as Ripk1 and Ripk3, respectively) and RIP1-RIP3 co-localization in vitro in PDA cells ( Fig. 1h , i). Chemotherapy also induced components of the necrosome in human PDA cells, whereas MLKL inhibition prevented chemotherapy-induced cell death in human PDA cells ( Fig. 1j, k) .
As necroptosis is a pro-inflammatory process, we postulated that it would support peri-tumoral inflammation 6 . We found that CXCL1 is one of the most highly expressed chemokines in mouse PDA ( Fig. 2a) . Similarly, CXCL1 was robustly expressed in human PDA ( Fig. 2b-d) . Gemcitabine upregulated the expression of CXCL1 in PDA in mice ( Fig. 2e ), whereas RIP3 deletion reduced CXCL1 expression in vivo (Fig. 2f , g) and in vitro (Fig. 2h ). High RIP3 expression also correlated with high CXCL1 expression in a human PDA RNA sequencing (RNA-seq) database ( Fig. 2i ). Furthermore, upregulation of CXCL1 by gemcitabine was reduced by RIP3 deletion in vivo (Fig. 2j ) and by RIP1 or RIP3 inhibition in vitro (Fig. 2k ). Collectively, these data are consistent with necrosome-dependent upregulation of CXCL1 in PDA.
We studied the effects of RIP3 deletion on the properties of in vitro cultured Kras G12D -transformed pancreatic ductal epithelial cells (Kras G12D PDEC). As expected, RIP3 deletion increased the proliferative rate of Kras G12D PDEC in vitro (Extended Data Fig. 1a ). Moreover, Kras G12D ;Rip3 −/− PDEC exhibited a distinct phenotype including loss of CDK4 and elevated expression of Bcl-xL and c-Myc (Extended Data Fig. 1b ), which are associated with aggressive tumour biology in PDA [7] [8] [9] [10] [11] .
As RIP3 deletion increased the proliferation of PDA cells, we postulated that blockade of necroptosis in vivo would accelerate tumorigenesis. To test this theory, we compared the rate of oncogenic progression in p48 Cre ;Kras G12D ;Rip3 +/+ and p48 Cre ;Kras G12D ;Rip3 −/− pancreases, which develop pancreatic neoplasia endogenously by expressing mutant Kras in the progenitor cells of the pancreas. Contrary to our hypothesis and belying our in vitro findings, RIP3 deletion protected against oncogenesis. p48 Cre ;Kras G12D ;Rip3 −/− pancreases showed a diminished rate of acinar replacement by dysplastic ducts, slower PanIN (pancreatic intraepithelial neoplasia) progression, and reduced fibro-inflammatory changes compared with p48 Cre ;Kras G12D ;Rip3 +/+ pancreases ( Fig. 3a and Extended Data Fig. 1c ). Accordingly, agedmatched p48 Cre ;Kras G12D ;Rip3 −/− pancreases weighed less than controls and RIP3 deletion extended survival (Fig. 3b, c) . The rate of proliferation was similar in p48 Cre ;Kras G12D ;Rip3 +/+ and p48 Cre ;Kras G12D ;Rip3 −/− pancreatic epithelial cells in vivo (Fig. 3d ). To test whether abrogation of RIP1 signalling also protected against PDA, we treated 6-week-old Letter reSeArCH KC mice for 8 weeks with the RIP1 inhibitor Nec-1s. Nec-1s treatment protected against oncogenic progression, as assessed by pancreas weight and histology ( Fig. 3e, f) .
As necroptosis can increase inflammation 12 , we postulated that RIP3 deletion protects against tumour progression by enhancing peri-tumoral immunogenicity. RIP3 deletion diminished infiltration by tumour-associated macrophages (TAMs; Extended Data Fig. 2a ). Conversely, the fractions of T cells and B cells were increased in p48 Cre ;Kras G12D ;Rip3 −/− pancreases (Extended Data Fig. 2b, c) . Analysis of the myeloid compartment showed a decreased fraction of myeloid-derived suppressor cells (MDSC) and dendritic cells in p48 Cre ;Kras G12D ;Rip3 −/− pancreases (Extended Data Fig. 2d, e ). Furthermore, consistent with our immunohistochemical data, the number of bulk tumour-infiltrating TAMs and their M2-like Arg1 + CD206 + subset were reduced by RIP3 deletion (Extended Data Fig. 2f -h). Macrophage expression of programmed death ligand 1 (PD-L1) was also reduced by RIP3 deletion (data not shown). Collectively, these data suggest that RIP3 deletion increases lymphocyte infiltration in PDA and reduces infiltration by immunosuppressive subsets of myeloid cells. Similarly, in human PDA, high RIP1-RIP3 co-expression correlated with elevated expression of the myeloid cell marker CD11b (also known as ITGAM) (Extended Data Fig. 2i ).
To determine whether deletion of RIP3 in the epithelial compartment alone is sufficient to protect against oncogenesis, we challenged wildtype mice with an orthotopic injection of either Kras G12D ;Rip3 +/+ PDEC or Kras G12D ;Rip3 −/− PDEC. Similar to our findings using pan-RIP3 deletion, Kras G12D ;Rip3 −/− tumours grew more slowly than Kras G12D ;Rip3 +/+ tumours ( Fig. 4a ), suggesting that RIP3 blockade in the epithelial compartment alone protects against PDA progression.
As inflammatory cells in the PDA tumour microenvironment (TME) express the components of the necrosome (Figs 1a and 4b, c), we investigated whether RIP3 deletion in the extra-epithelial compartment would similarly mitigate PDA progression. Wild-type and Rip3 −/− mice were challenged with orthotopic intra-pancreatic injection of Kras G12D PDEC or Pdx1 Cre ;Kras G12D ;Tp53 R172H (KPC-derived) PDA cells, which express both mutant Kras and p53 (also known as Trp53), and tumour size was measured 3 weeks later. Rip3 −/− mice developed smaller Kras G12D (not shown) and Pdx1 Cre ;Kras G12D ;Tp53 R172H tumours ( Fig. 4d ) than did wild-type mice, consistent with the idea that blockade of necroptosis in the extra-epithelial compartment alone can protect against PDA.
To determine whether deletion of RIP3 in the extra-epithelial compartment similarly bolsters peri-tumoral immunogenicity, we analysed the inflammatory infiltrate in orthotopic KPC tumours in wild-type and Rip3 −/− mice. RIP3 deletion resulted in elevated T cell and B cell infiltrates ( Fig. 4e , f); peri-tumoral T cells expressed less IL-10 and PD-1 and more CD44, and included a lower fraction of T regulatory (T reg ) cells, in Rip3 −/− mice than in wild-type mice ( Fig. 4g , h; Extended Data Fig. 3a-d ). Analysis of the myeloid compartment again revealed a reduction in the fraction of peri-tumoral MDSC ( Fig. 4i ) and TAMs ( Fig. 4j) , with a shift towards an M1-like phenotype (Fig. 4k , l) and reduced PD-L1 expression ( Fig. 4m ). These data appear to conflict with the recent finding that RIP1 signalling can enhance CD8 + T cell cross-priming 13 . However, the effects in PDA may be unique to the immunological milieu of the pancreatic TME. Accordingly, RIP3 deletion was not protective against B16 melanoma or subcutaneously implanted KPC cells (Extended Data Fig. 3e , f).
As CXCL1 expression in PDA depends on the necrosome (Fig. 2 ) and we found that CXCR2 is widely expressed on peri-tumoral leukocytes (Extended Data Fig. 4a, b ), we postulated that CXCL1 could mediate the Figure 1 | RIP1 and RIP3 expression in PDA. a, b, Paraffin-embedded sections of human PDA and surrounding normal pancreas tissue from ten patients with PDA were tested for expression of RIP1 and RIP3. Representative images (a) and summary data (b) are shown. The magnification of isotype control slides are 4.5 times smaller than experimental slides. HPF, high-power field. c, Human PDA specimens and adjacent normal human pancreas tissue were tested for expression of RIP1, RIP3, FADD, MLKL, and cleaved caspase 8 (CASP8) by western blotting. Representative data from two patients and density analysis from four patients are shown. d, Frozen human PDA specimens were tested for RIP1 and RIP3 co-expression by immunofluorescence microscopy. A representative image is shown. Nuclei counterstained with 4′ ,6diamidino-2-phenylindole (DAPI). e, Frozen sections of pancreas from 6-month-old p48 Cre ;Kras G12D (KC) mice, which express mutant Kras, were tested for RIP1 and RIP3 co-localization. f, Pdx1 Cre ;Kras G12D ;Tp53 R172H (KPC) mice, which express mutant Kras and p53, were serially treated with gemcitabine (Gem.) or PBS and tested for expression of RIP1 and RIP3 by IHC (n = 3 per group). g, Orthotopically implanted KPC-derived tumours were removed from gemcitabine-or PBS-treated mice and tested for RIP1 and RIP3 expression by western blotting. Representative data and averages of quadruplicates based on density analysis are shown. h, KPC-derived tumour cells were treated with gemcitabine or PBS in vitro in triplicate and tested for gene expression by quantitative PCR (qPCR). i, Lysate from Pdx1 Cre ;Kras G12D ;Tp53 R172H tumour cells that had been treated with PBS or gemcitabine was immunoprecipitated with control or anti-RIP1 antibodies (Ab) and tested for expression of RIP1 and RIP3. Input controls were also probed. j, Human AsPC-1 cells were treated with PBS or gemcitabine in triplicate and tested for gene expression by qPCR. k, AsPC-1, PANC1, and MIA PaCa-2 cells were cultured with PBS, gemcitabine, or gemcitabine and an MLKL inhibitor in quadruplicate. Cellular viability was determined at 24 h using propidium iodide (PI) staining. Graphs show mean ± s.e.m. n.s., not significant; * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001 (unpaired t-test). For gel source data, see Supplementary Fig. 1 
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pro-tumorigenic immune suppression associated with RIP3 signalling by mobilizing myeloid cells 14, 15 . To test this hypothesis, we challenged wild-type mice with orthotopic PDA while blocking CXCL1. CXCL1 blockade protected against tumorigenesis induced by either orthotopic Kras G12D PDEC (data not shown) or KPC cells (Extended Data Fig. 4c ). However, anti-CXCL1 treatment did not further enhance tumour protection in Rip3 −/− mice (Extended Data Fig. 4d ). Moreover, like RIP3 deletion, CXCL1 blockade reduced MDSC and TAM accumulation (Extended Data Fig. 4e, f ). Tumour-infiltrating T cells were also more activated in mice in which CXCL1 was blocked than in control mice, as shown by higher CD44 and TNFα expression (Extended Data Fig. 4g , h). However, CXCL1 inhibition was not significantly associated with increased infiltration of peri-tumoral T cells (Extended Data Fig. 4i ); nor did it diminish T reg cell accumulation or IL-10 expression (data not shown), unlike RIP3 deletion. Together, these data suggest that CXCL1 overexpression alone may i , Human PDA tumours were tested for co-expression of CXCL1 and CK19 or CXCL1 and CD45 by confocal microscopy. Representative images are shown. c, Paraffin-embedded PDA sections from ten patients were tested for expression of CXCL1 by IHC and compared with surrounding normal pancreas. Representative ductal and stromal areas of PDA tumours and quantitative data are shown. The magnification of the isotype control insert is 4.5 times smaller than experimental slides. d, CXCL1 levels in tissue homogenate from three human PDA specimens were tested by ELISA and compared with surrounding normal pancreas. e, Homogenized KPC tumours from PBS-or gemcitabine-treated mice were tested for CXCL1 by ELISA. Experiments were performed in biological duplicates. f, Paraffin-embedded sections from 6-month-old p48 Cre ;Kras G12D ;Rip3 +/+ (KC;Rip3 +/+ ) and p48 Cre ;Kras G12D ;Rip3 −/− mice were tested for expression of CXCL1 by IHC (n = 3 per group). g, Homogenized pancreas tissue from 6-month-old wild-type (WT) (n = 6), p48 Cre ;Kras G12D ;Rip3 +/+ (n = 4), and p48 Cre ;Kras G12D ;Rip3 −/− (n = 4) mice was tested for CXCL1 by ELISA. h, Kras G12D ;Rip3 +/+ PDEC (n = 3) and Kras G12D ;Rip3 −/− PDEC (n = 4) were cultured in vitro for 24 h and the supernatant was tested for CXCL1 by ELISA. PDEC, pancreatic ductal epithelial cells. i, Correlation between high and low tertiles of RIP3 expression and CXCL1 expression in human PDA tissues tested using the UCSC RNA-seq database. Each point represents data from one patient. j, Wild-type or Rip3 −/− mice were orthotopically implanted with KPC-derived tumour cells and treated with a single dose of gemcitabine or PBS 3 weeks later. Tumours were removed 12 h after treatment and homogenized, and the fold-difference in CXCL1 expression between gemcitabine-and PBS-treated tumours from wildtype and Rip3 −/− mice was determined by ELISA (n = 5). k, KPC-derived tumour cells were treated in triplicate in vitro with gemcitabine (10 μ M or 50 μ M), Nec-1s, or a RIP3 inhibitor (RIP3-Inh.), alone or in combination. CXCL1 levels were tested after 24 h by ELISA. Experiments were repeated at least twice. Graphs show mean ± s.e.m. n.s., not significant; * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001 (unpaired t-test). Letter reSeArCH not account for the entire immunosuppressive phenotype associated with intact necroptosis signalling in PDA.
We postulated that necroptotic tumour cells release soluble factors that induce peri-tumoral immune suppression. Mincle, a C-type lectin receptor (CLR) that is crucial for immunity to mycobacteria, can promote sterile inflammation in vitro by ligating SAP130, a nuclear protein released from dying cells 16, 17 . We discovered high cytoplasmic SAP130 expression in human PDA (Extended Data Fig. 5a ). SAP130 expression was also upregulated by gemcitabine treatment in human PDA cell lines (Extended Data Fig. 5b ). Furthermore, SAP130 was highly expressed in p48 Cre ;Kras G12D ;Rip3 +/+ pancreases, whereas its expression was reduced in p48 Cre ;Kras G12D ;Rip3 −/− pancreases (Extended Data Fig. 5c ). Similarly, gemcitabine-induced upregulation of Sap130 was reduced by Nec-1s in mouse PDA cells (Extended Data Fig. 5d ). SAP130 was expressed in both epithelial and inflammatory cells of PDA (Extended Data Fig. 5e, f ) . Moreover, confocal microscopy suggested that SAP130 co-localized with RIP1/RIP3 in human (Extended Data Fig. 5g ) and mouse (data not shown) PDA cells. SAP130 expression also correlated with RIP1-RIP3 co-expression in a human RNA-seq database (Extended Data Fig. 5h ). Notably, there was a trend towards an association between high SAP130 expression and low survival in humans with PDA (Extended Data Fig. 5i ).
We postulated that ligation of Mincle by SAP130 drives necrosomeinduced accelerated oncogenesis. Consistent with this idea, immunoprecipitation experiments indicated that Mincle is associated with SAP130 in PDA (Extended Data Fig. 5j ). Mincle was expressed in inflammatory cells in the human PDA TME, but not in transformed ductal cells or in normal pancreas cells (Extended Data Fig. 6a ). Overall, around 10% of tumour-infiltrating leukocytes expressed Mincle in human PDA compared with < 1% of peripheral blood mononuclear cells (PBMC; Extended Data Fig. 6b ). Subset analysis revealed that Mincle expression was higher in human CD14 + CD15 + tumour-infiltrating monocytes than in PBMC (Extended Data Fig. 6c ). Similarly, in KC mice 10-15% of pancreatic leukocytes expressed Mincle compared with ~ 3% expression in the spleen and < 1% expression in pancreatic parenchymal cells (Extended Data Fig. 6d ). Immunofluorescence microscopy confirmed that Mincle was expressed in enriched PDA-infiltrating leukocytes (Extended Data Fig. 6e ). Subset analysis indicated that Mincle was more highly expressed in PDA-infiltrating MDSC, dendritic cells, and macrophages than in these cellular subsets in the spleen (Extended Data Fig. 6f ). Western blotting showed RIP3-dependent elevated expression of Mincle-related signalling intermediates in PDA (Extended Data Fig. 6g ). Accordingly, there were few phosphorylated Syk + leukocytes in p48 Cre ;Kras G12D ;Rip3 −/− and p48 Cre ;Kras G12D ;Mincle −/− (Mincle is also known as Clec4e) pancreases compared to p48 Cre ;Kras G12D ;Rip3 +/+ ; Mincle +/+ pancreases (Extended Data Fig. 6h ). However, deletion of Mincle in PDA did not reduce CXCL1 expression (Extended Data Fig. 6i ), and CXCL1 blockade did not alter the expression of Mincleassociated signalling intermediates (data not shown).
To determine whether Mincle signalling accelerates oncogenesis, we treated 6-week-old KC mice thrice weekly with the Mincle ligand TDB (trehalose-6,6-dibehenate), which we confirmed induced phosphorylation of Syk in vivo (Extended Data Fig. 7a ). Mincle ligation accelerated tumorigenesis, which resulted in higher grade PanIN lesions, extensive fibrosis, and scattered foci of invasion when compared with control mice (Extended Data Fig. 7b ). TDB also accelerated the growth of orthotopically implanted KPC-derived tumours in wild-type (not shown) and Rip3 −/− mice (Extended Data Fig. 7c ), suggesting that the pro-tumorigenic effects of Mincle activation in PDA are either independent of or downstream of RIP3 signalling. Moreover, the inflammatory TME in TDB-treated Rip3 −/− pancreases recapitulated the immune-suppressive milieu associated with intact necroptosis signalling. Specifically, TDB-treated pancreases trended to contain a lower fraction of tumour-infiltrating T cells (Extended Data Fig. 7d ) and exhibited increased recruitment of both MDSC (Extended Data Fig. 7e ) and M2-like TAMs, which expressed high PD-L1, compared with control pancreases (Extended Data Fig. 7f-i) . Similarly, direct inoculation of orthotopic PDA tumours with recombinant SAP130 accelerated PDA growth in wild-type and Rip3 −/− mice but not in Mincle −/− mice (Extended Data Fig. 7j ) and recruited an immune-suppressive infiltrate in WT mice (Extended Data Fig. 7k, l) .
To determine whether Mincle signalling is required for PDA progression, we crossed Mincle −/− and KC mice and analysed pancreases at 3 month intervals. Mincle deletion slowed the rate of oncogenesis based on histological analysis, pancreas weight, and animal survival (Extended Data Fig. 8a-c) . Similarly, orthotopic KPC-derived tumour implantation in the pancreases of Mincle −/− mice resulted in smaller tumours and prolonged survival compared with implantation in wild-type mice (Extended Data Fig. 8d, e ). However, the survival b, Frozen sections of orthotopic KPC tumours were co-stained for RIP1, RIP3, and CD45 and imaged by immune-fluorescence microscopy. c, CD45 + leukocyte suspensions harvested from orthotopic KPC tumours were co-stained for RIP1 and RIP3 and imaged by immune-fluorescence microscopy. d, WT and RIP3 −/− mice bearing orthotopic KPC tumours were killed at 3 weeks. Representative gross pictures and tumour weights are shown (n = 9 per group). e-h, The fractions of peri-tumoral CD3 + T cells (e) and CD19 + B cells (f) and the T cell expression of IL-10 (g) and PD-1 (h) from orthotopic KPC tumours. SSC, side scatter. i, j, The fraction of peri-tumoral Gr1 + CD11b + MDSC (i) and Gr1 − CD11b + F4/80 + TAMs (j). k-m, Expression of MHC II (k), CD204 (l), and PD-L1 (m) on TAMs. Flow cytometry data were reproduced in three separate experiments. Graphs show mean ± s.e.m. * P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t-test). 
Tumour weight (mg) ***
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Letter reSeArCH benefit was not as pronounced in Mincle −/− mice as in Rip3 −/− mice. Moreover, experiments involving orthotopic implantation of Kras G12D PDEC suggested that combined blockade of both CXCL1 and Mincle had additive protective effects over RIP3 blockade alone, whereas combined blockade of RIP3 and Mincle or RIP3 and CXCL1 did not (Extended Data Fig. 8f ).
To determine whether Mincle deletion mimics the immunogenic reprogramming of the TME that is associated with RIP3 deletion, we assayed the pancreatic infiltrate in p48 Cre ;Kras G12D ;Mincle −/− mice. Immunohistochemical (IHC) analysis of p48 Cre ;Kras G12D ;Mincle −/− pancreases showed diminished TAM infiltration but increased T cell recruitment (Extended Data Fig. 9a ). Flow cytometry confirmed that Mincle deletion was associated with increased immunogenic T cell infiltration (Extended Data Fig. 9b-d) , diminished MDSC infiltration (Extended Data Fig. 9e ), a trend towards a reduction in the number of dendritic cells (Extended Data Fig. 9f) , and a decreased fraction of TAMs (Extended Data Fig. 9g ) with M1-like polarization (Extended Data Fig. 9h, i) and reduced PD-L1 expression (data not shown). These changes recapitulate the immunogenic reprogramming of the TME that follows RIP3 deletion.
To investigate whether protection against oncogenesis in the absence of RIP3 or Mincle signalling is T cell dependent, we depleted T cells and implanted orthotopic KPC tumours in wild-type, Rip3 −/− , and Mincle −/− mice. T cell depletion did not influence PDA growth in wild-type mice. However, protection against tumour growth was abrogated by T cell depletion in Rip3 −/− and Mincle −/− mice (Extended Data Fig. 10a ). Conversely, depletion of macrophages in wild-type mice led to T cell activation and protection against tumour growth; however, macrophage depletion did not enhance T cell activation or induce protection against oncogenesis in Rip3 −/− or Mincle −/− mice (Extended Data Fig. 10b, c) . These data suggest that, in wild-type mice bearing orthotopic tumours, TAMs promote PDA progression and T cells are not tumour-protective; conversely, in the absence of RIP3 or Mincle signalling, macrophages surrender their tumour-promoting effects and T cells are reprogrammed into indispensable mediators of anti-tumour immunity. Collectively, our findings indicate that necroptosis-induced CXCL1 and Mincle signalling promotes myeloid cell-induced adaptive immune suppression in PDA. Each of these networks represents a novel target for experimental therapeutic agents (Extended Data Fig. 10d ).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Permeabilization Solution Kit (BD Biosciences). Flow cytometry was carried out on the LSR-II flow cytometer (BD Biosciences). Data were analysed using FlowJo v.7.6.5 (Treestar, Ashland, OR). Western blotting and immunoprecipitation. To extract proteins from tissues, 15-30 mg of tissue was homogenized in 150-300 μ l (that is, 10 times the weight) ice-cold RIPA buffer. Total protein was quantified using the BioRad DC Protein Assay according to the manufacturer's instructions (BioRad, Hercules, CA). Western blotting was performed as described previously with minor modifications 24 . Briefly, 10% Bis-Tris polyacrylamide gels (NuPage, Invitrogen) were equiloaded with 10-30 μ g protein, electrophoresed at 200 V, and electrotransferred to PVDF membranes. After blocking with 5% BSA, membranes were probed with primary antibodies to β -actin (8H10D10), FADD (polyclonal), RIP1 (D94C12), caspase-8 (D35G2), PLC-γ (polyclonal), p-PLC-γ (polyclonal), Bcl-xL (54H6; all Cell Signaling, Beverly, MA), RIP3 (polyclonal; Abgent, San Diego, CA), c-Myc (9E10), CDK4 (C-22), CARD9 (polyclonal), Syk (polyclonal), p-Syk (polyclonal), Rb (C-15), SAP130 (H-300), Mincle (H-46; all Santa Cruz Biotechnologies, Dallas, TX), and MLKL (polyclonal; Abcam). Blots were developed by ECL (Thermo Scientific, Asheville, NC). For immunoprecipitation experiments, RIP1 or SAP130 was precipitated with protein G-agarose from cells. Immunoprecipitates were re-suspended and heated in loading buffer under reduced conditions, and resolved by 10% SDS-PAGE before transfer to PVDF membranes. The presence of co-immunoprecipitated RIP3 or Mincle, respectively, was determined by western blotting. Histology, immunohistochemistry, and microscopy. For histological analysis, pancreatic specimens were fixed with 10% buffered formalin, dehydrated in ethanol, embedded with paraffin, and stained with H&E or Gomori's trichrome. The fraction of preserved acinar area was calculated as previously described 24 . Pancreatic ductal dysplasia was graded according to established criteria 25 . Immunohistochemistry in mouse tissues was performed using antibodies directed against F4/80 (CI:A3-1; Abcam), CD3 (polyclonal; Abcam), Arg1 (EPR6671(B); Abcam), SAP130 (polyclonal; Abcam), Mincle (AT16E3; Abcam), p-Syk (polyclonal; Abcam), Ki67 (polyclonal; Abcam), and CXCL1 (polyclonal, Abcam). For analysis of human tissue, de-identified paraffin-embedded human PDA specimens and samples of surrounding non-tumorous tissue from ten consecutive patients who underwent surgical resection of PDA at NYU Medical Center were probed with antibodies directed against RIP1 (D94C12; Cell Signaling), RIP3 (Q9Y572; Abgent), Mincle (AT16E3; Abcam), CXCL1 (polyclonal; Abcam), and SAP130 (polyclonal; Abcam). All human tissues were collected using an IRB approved protocol and donors of de-identified specimens gave informed consent. Sample sizes for human experiments were not determined based on formal power calculations. Quantifications were performed by assessing ten high-power fields (HPF; 40×) per slide in a blinded manner. Immunofluorescent staining of frozen mouse tissues or cells was performed using antibodies against Mincle (AT16E3, Acris Antibodies), RIP1 (polyclonal, Bioss), RIP3 (polyclonal, Bioss), CD45 (30-F11; BD Biosciences), CK19 (clone 13, Abnova), CXCL1 (polyclonal; Abcam), CXCR2 (SA045E1; BioLegend), SAP130 (polyclonal; Abcam), and DAPI (Vector Labs, Burlingame, CA). Immunofluorescent images were acquired using a Zeiss LSM700 confocal microscope with ZEN 2010 software (Carl Zeiss, Thornwood, New York). PCR. RNA was extracted using the RNeasy Mini kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. RNA was converted to cDNA using the RT2 First Strand Kit (Qiagen). qPCR was performed using RT2 SYBR Green qPCR mastermix (Qiagen) on a Stratagene MX3005P (Stratagene, La Jolla, CA) according to the manufacturers' protocols. Primers used for human and mouse samples (RIP1, RIP3, CASP8, FADD, CXCL1, and SAP130) were purchased from Qiagen. Expression levels were normalized to β -actin (ACTβ) and expressed as fold change compared to control. Human database and statistical analysis. Human RNA-seq data and clinical correlations were performed using the UCSC Cancer Genomics Browser (https:// genome-cancer.ucsc.edu/) 26 . Data are presented as mean ± s.e.m. Survival was measured using the Kaplan-Meier method. Statistical significance was determined by Student's t-test and the log-rank test using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). P < 0.05 was considered significant.
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Animals and in vivo models. C57BL/6 (H-2Kb) mice were purchased from Jackson Labs (Bar Harbour, ME). Mincle −/− mice were obtained from the MMRRC (San Diego, CA) 17 . Rip3 −/− mice were obtained from Genentech (San Francisco, CA) 18 . KC (gift from D. Bar-Sagi, New York University) and KPC (gift from M. Philips, New York University) mice develop pancreatic neoplasia endogenously by expressing mutant Kras alone or mutant Kras and p53, respectively, in the progenitor cells of the pancreas 19, 20 . Both male and female mice were used but animals were sex-and age-matched in each experiment. Randomization was not performed. There were no specific inclusion or exclusion criteria. Sample sizes for experiments were determined without formal power calculations. Survival data for control KC mice have been previously reported 21 . For orthotopic pancreatic tumour challenge, mice were given intra-pancreatic injections of either Kras G12D PDEC or FC1242 tumour cells derived from KPC mice. Kras G12D PDEC and FC1242 cells were generated as previously described 21, 22 . In preparation for intra-pancreatic injection, cells were suspended in PBS with 50% Matrigel (BD Biosciences, Franklin Lakes, NJ) at 1 × 10 6 cells ml −1 and 1 × 10 5 cells were injected into the body of the pancreas via laparotomy. Age-matched mice were used between 8 and 10 weeks of age for orthotopic tumour experiments. Mice were killed by cervical dislocation 3-6 weeks later and tumour volume recorded.
To study the effects of Mincle ligation, mice were injected intraperitoneally (i.p.) with TDB (4 mg kg −1 ; Invivogen, San Diego, CA) thrice weekly for 8 weeks in the endogenous tumour models and for 3 weeks in the orthotopic tumour models.
In other experiments, orthotopic tumours were serially treated with direct inoculation of recombinant SAP130 (22 μ g; MyBioSource, San Diego, CA) at oneweek intervals via mini-laparotomy. In select experiments, cohorts of mice were treated daily with the RIP1 inhibitor Nec-1s (2 mg kg −1 , i.p.; BioVision, Milpitas, CA) or a neutralizing anti-CXCL1 monoclonal antibody (mAb) (4 mg kg −1 , i.v.; R&D Systems). Gemcitabine (100 mg kg −1 , i.p.; Hospira, Lake Forest, IL) was administered in vivo to KPC mice three times at 72-h intervals unless otherwise specified. T cells (T24/31) and macrophages (F4/80, both BioXcell) were depleted with neutralizing mAbs as previously described 23 . In some experiments, mice were subcutaneously administered FC1242 cells (1 × 10 6 ) or B16 melanoma cells (1 × 10 6 ; gift from R. DeMatteo, Memorial Sloan-Kettering Cancer Center) and killed 18 days later. Investigators were not blinded to group allocation but were blinded when assessing outcome. All animal procedures were approved by the New York University School of Medicine IACUC. The maximum tumour size permitted was 3 cm 3 and this was not exceeded. Cell lines and in vitro experiments. The human PDA cell lines AsPC-1, PANC1, and MIA PaCa-2 (gifts from D. Bar-Sagi, originally obtained from ATCC) were maintained in complete RPMI (RPMI 1640 with 10% heat-inactivated FBS, 2 mM l-glutamine, 1% penicillin/streptomycin). Cell lines were not authenticated. Cells were free of mycoplasma. In selected experiments, cells were treated with gemcitabine (10-50 μ M), Nec-1s (50 μ M), a RIP3 inhibitor (GSK872; 6 μ M), or a MLKL inhibitor (necrosulphonamide, 1 μ M, both EMD Millipore, Billerica, MA). Cell viability was determined by PI staining. Cellular proliferation was assessed using the XTT II assay according to the manufacturer's protocol (Roche, Pleasanton, CA) and expressed as per cent proliferation compared to control. Inflammatory mediators in cell culture supernatant were measured using the Milliplex Immunoassay (Millipore, Billerica, MA). CXCL1 was additionally measured using Flexbeads (BD Biosciences) and ELISA (R&D Systems). Cellular harvest and flow cytometry. Human and mouse single cell suspensions for flow cytometry were prepared as described previously with slight modifications 24 . Briefly, pancreases were placed in cold RPMI 1640 with 1 mg ml −1 collagenase IV (Worthington Biochemical, Lakewood, NJ) and 2 U ml −1 DNase I (Promega, Madison, WI) and minced with scissors to sub-millimetre pieces. Tissues were then incubated at 37 °C for 30 min with gentle shaking every 5 min. Specimens were passed through a 100-μ m mesh, and centrifuged at 350g for 5 min. The cell pellet was resuspended in cold PBS with 1% FBS. After blocking Fcγ RIII/II with an anti-CD16/CD32 mAb (eBioscience, San Diego, CA), cell labelling was performed by incubating 10 6 cells with 1 μ g fluorescently conjugated mAbs directed against mouse CD44 (IM7), CD206 (C068C2), PD-L1 (10F.9G2), PD-1 (29F.1A12), CD3 (17A2), CD4 (RM4-5), CD8 (53-6.7), CD45 (30-F11), CD11b (M1/70), Gr1 (RB6-8C5), CD11c (N418), MHC II (M5/114.15.2), IL-10 (JES5-16E3), IFN-γ (XMG1.2), TNFα (MP6-XT22), F4/80 (BM8), CD19 (6D5; all Biolegend, San Diego, CA), p-Syk (moch1ct, eBioscience), and CD204 (2F8; Acris Antibodies, San Diego, CA). mAbs directed against Mincle (4A9, MBL International Corporation, Woburn, MA) were conjugated to FITC using the FITC Conjugation Kit (Abcam, Cambridge, MA). Human pancreas and PBMC were stained with mAbs directed against CD45 (HI30), CD14 (HCD14), CD15 (W6D3), CD19 (H1B19), CD11b (M1/70), CD11c (3.9), MHC II (L243; all Biolegend) and Mincle (AT16E3; Acris Antibodies). Intracellular cytokine staining was performed using the Fixation/ 
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Extended Data Figure 1 | RIP3 deletion in PDA induces an aggressive tumour phenotype in vitro but mitigates oncogenesis in vivo. a, Kras G12D ;Rip3 +/+ and Kras G12D ;Rip3 −/− PDEC were cultured at equal densities and tested for proliferation after 24 h using the XTT assay (n = 6 per group). b, Lysate was harvested from Kras G12D ;Rip3 +/+ and Kras G12D ;Rip3 −/− PDEC and tested for expression of selected tumour suppressor and oncogenic genes. Representative data and density plots from biological duplicates are shown. Experiments were reproduced three times. c, p48 Cre ;Kras G12D ;Rip3 +/+ (n = 11) and p48 Cre ;Kras G12D ;Rip3 −/− (n = 9) mice were killed at 3, 6, or 9 months of age. Representative trichrome-stained sections are shown and the fraction of fibrotic pancreatic area was calculated for each cohort. Graphs show mean ± s.e.m. ns, not significant; * P < 0.05, * * * P < 0.001, * * * * P < 0.0001 (unpaired t-test). For gel source data, see Supplementary Fig. 1 .
Extended Data Figure 5 | High SAP130 levels in PDA. a, Paraffinembedded sections of human PDA and surrounding normal pancreas tissue were tested for expression of SAP130 by IHC compared with isotype control. Representative images and summary data from ten patients with PDA are shown. b, SAP130 expression was measured by qPCR in human AsPC-1 cells after treatment with PBS or gemcitabine (n = 3 per group). c, SAP130 expression was assayed by IHC in paraffinembedded pancreases from 6-month-old p48 Cre ;Kras G12D ;Rip3 +/+ , p48 Cre ;Kras G12D ;Rip3 −/− , and wild-type mice (n = 4 per group) compared with respective isotype controls. Representative images and quantitative data are shown. d, Sap130 expression was tested by qPCR in KPC-derived tumour cells treated with PBS or gemcitabine with or without Nec-1s in triplicate. e, f, SAP130 expression was tested by confocal microscopy in CK19 + epithelial cells (e) and CD45 + inflammatory cells (f) in mouse PDA. g, Co-expression of SAP130, RIP1, and RIP3 was tested by confocal microscopy in human PDA. h, Correlation between high and low tertiles of combined RIP1/RIP3 and SAP130 expression was tested using the UCSC RNA-seq database. Graphs show mean ± s.e.m. *P < 0.05, ****P < 0.0001 (unpaired t-test). i, Patients with PDA with high or low tertile levels of SAP130 expression were compared in a Kaplan-Meier survival analysis using the UCSC RNA-seq database. j, Pancreas lysate from 6-month-old wild-type or KC mice was immunoprecipitated using an anti-SAP130 or control antibody and then tested for expression of SAP130 and Mincle. Input controls were similarly probed. Results were reproduced in two separate experiments. For gel source data, see Supplementary Fig. 1 .
